

## ASX Announcement

### Brazil Patent Granted for RECCE® Anti-Infectives

**Sydney Australia, 24 March 2026:** Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) (**Recce or the Company**), a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the Brazilian National Institute of Industrial Property (INPI) has formally granted a Family 4 patent for Recce's Anti-Infectives, expiry 2041.

The Brazilian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:

- **Process for preparation of RECCE® anti-infectives**
- **Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more**
- Specifically, further validating RECCE® anti-infectives from studies in **Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Diabetic Foot Infections (DFI), Burn Wounds, Lung Infections (including Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia), Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV-2**
- **Administration by oral, inhalation, transdermal delivery or by injection (into the bloodstream, intramuscular and/or intravenous)**
- **Administration may also be supplied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)**

This is the Company's seventh Family 4 patent, alongside Australia, Canada, China, Hong Kong, Israel and Japan with further Patent Cooperation Treaty (PCT) submissions in respective stages of review/allowed.



**ASX:** RCE, **FSE:** R9Q

**Head Office:** Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Recce's intellectual property portfolio is focused on protection in leading antibiotic markets, with Brazil being one of the world's largest and the largest in South America.<sup>1</sup> The Brazilian antibiotics market generated revenue of USD 774.5 million (≈AUD 1.09 billion) in 2024 and is expected to reach USD 964.3 million (≈AUD 1.36 billion) by 2033, growing at a compound annual growth rate (CAGR) of 2.4% from 2025 to 2033.<sup>2</sup>

**Recce Pharmaceuticals' Chief Executive Officer, James Graham said:** "We thank the Brazilian National Institute of Industrial Property for their recognition of Recce's platform technology. Patent protection is fundamental to Recce, and we are encouraged by the expansion of our patent portfolio into Brazil, South America's largest antibiotic market. As we look to address the urgent and growing global burden of antibiotic-resistant superbugs, this granted patent is yet another intellectual property milestone."

This announcement has been approved for release by Recce Pharmaceuticals Board.

<sup>1</sup> <https://www.precedenceresearch.com/antibiotics-market>

<sup>2</sup> <https://www.grandviewresearch.com/horizon/outlook/antibiotics-market/brazil>



#### Media and Investor Relations

**Chief Executive Officer**  
James Graham  
Recce Pharmaceuticals Ltd  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

**Australia**  
Andrew Geddes  
Seed Media  
[andrew@seedmedia.com.au](mailto:andrew@seedmedia.com.au)

**USA & Europe**  
Guillaume van Renterghem  
LifeSci Advisors  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

### Media and Investor Relations

**Chief Executive Officer**  
James Graham  
Recce Pharmaceuticals Ltd  
james.graham@recce.com.au

**Australia**  
Andrew Geddes  
Seed Media  
andrew@seedmedia.com.au

**USA & Europe**  
Guillaume van Renterghem  
LifeSci Advisors  
gvanrenterghem@lifesciadvisors.com